查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609465

焦慮症及憂鬱症治療市場:各類藥物，各適應症，各年齡層，症狀重症度別，各流通管道，各地區，機會，預測，2018年～2032年

Anxiety Disorders and Depression Treatment Market Assessment, By Drug Class, By Indication, By Age Group, By Condition Severity, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 235 Pages | 商品交期: 3-5個工作天內

價格

2025-2032年預測期間，全球焦慮症和憂鬱症治療市場規模將以複合年增長率14.70%增長，從2024年的132.6億美元增長到2032年的397.2億美元。萬美元。市場的成長是由於人們對各種精神疾病的認識不斷提高、各年齡層患者抑鬱和焦慮病例的增加以及對解決精神健康問題的有效治療解決方案的需求不斷增長，其中包括政府不斷增加的需求和支持努力。此外，先進診斷技術的可用性允許及早發現病情並及時幹預。

與焦慮相關的疾病病例的增加是由於經濟和學業壓力的增加以及媒體多任務處理的迅速擴展造成的。根據美國精神醫學會 2024 年年度心理健康調查結果，美國成年人越來越常遭受焦慮之苦。該國約 43% 的成年人表示，他們比前一年感到更加焦慮，高於 2022 年的 32%。精神健康問題的盛行率不斷上升，各組織不斷努力消除對心理障礙尋求幫助的污名化，再加上普通民眾意識的提高，導致全球焦慮和抑鬱的治療量下降。

此外，世界各地的製藥公司都在大力投資開發針對焦慮症和憂鬱症的新型治療解決方案，為全球焦慮症和憂鬱症治療市場提供了利潤豐厚的成長機會。 2024 年 3 月，Engrail Therapeutics 成功籌集了 1.57 億美元的創投資金，以支持其神經發育和神經精神疾病的產品線。

本報告提供全球焦慮症及憂鬱症治療市場相關調查，提供市場概要，以及各類藥物，各適應症，各年齡層，症狀重症度別，各流通管道，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 全球焦慮症及憂鬱症治療市場預測，2018年～2032年

  • 市場規模的分析與預測
  • 市場佔有率分析與預測
  • 市場地圖分析，2024年
    • 各類藥物
    • 各適應症
    • 各年齡層
    • 症狀重症度別
    • 各流通管道
    • 各地區

第5章 北美的焦慮症及憂鬱症治療市場預測，2018年～2032年

第6章 歐洲的焦慮症及憂鬱症治療市場預測，2018年～2032年

第7章 亞太地區的焦慮症及憂鬱症治療市場預測，2018年～2032年

第8章 南美的焦慮症及憂鬱症治療市場預測，2018年～2032年

第9章 中東·非洲的焦慮症及憂鬱症治療市場預測，2018年～2032年

第10章 需求供給分析

第11章 價值鏈分析

第12章 波特的五力分析

第13章 大環境分析

第14章 價格分析

第15章 市場動態

第16章 市場趨勢與發展

第17章 法規結構和革新

第18章 專利的形勢

第19章 案例研究

第20章 競爭情形

  • 前五名市場領導的競爭矩陣
  • 前五名參與企業的SWOT分析
  • 前10名市場參與企業的形勢
    • AbbVie Inc.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca plc
    • Eli Lilly and Company
    • Johnson & Johnson Services, Inc.
    • H. Lundbeck A/S
    • Sanofi S.A.

第21章 策略性建議

第22章 諮詢方式和免責聲明

Product Code: MX12392

Global anxiety disorders and depression treatment market is projected to witness a CAGR of 14.70% during the forecast period 2025-2032, growing from USD 13.26 billion in 2024 to USD 39.72 billion in 2032. The growth of the market is supported by the rising awareness about different mental health disorders, rising cases of depression and anxiety in patients of all age groups, increasing requirement for effective therapeutic solutions to address mental health conditions, and supportive initiatives by both governmental and non-governmental organizations. Additionally, the availability of advanced diagnostic techniques allows the early identification of the conditions, resulting in prompt interventions.

The increasing cases of anxiety-related disorders can be attributed to the increasing levels of economic and academic stress and the rapid expansion of media multitasking. According to the 2024 American Psychiatric Association's annual mental health poll results, adults in the United States are increasingly suffering from anxiety. Approximately 43% of the adults in the country reported feeling more anxious than the previous year, up from 32% in 2022. The rising prevalence of mental health conditions and growing efforts of various organizations to destigmatize seeking help for psychological disorders, coupled with growing awareness among the general population, are bolstering the global anxiety disorders and depression treatment market size.

Pharmaceutical companies across the globe are also significantly investing in the development of novel therapeutic solutions for anxiety and depression, providing lucrative growth opportunities to the global anxiety disorders and depression treatment market. In March 2024, Engrail Therapeutics successfully raised USD 157 million in venture capital to support its product pipeline for neurodevelopmental and neuropsychiatric disorders.

Additionally, the growing popularity of telehealth services supports the market's expansion as patients prefer meeting mental health professionals online due to the convenience, comfort, and privacy offered by the service. These tools are making the management of mental health diseases more accessible and allowing patients in remote locations to receive professional help.

Increasing Awareness About Mental Health Disorders Boosts Market Demand

The increasing awareness about different mental health diseases and their impact on the overall well-being of a person is encouraging people living with mental health diseases to seek treatment and medication to manage their condition effectively. Moreover, various companies are launching campaigns related to mental health in the workplace, further propelling global anxiety disorders and depression treatment market growth. In October 2024, Maybelline New York, a cosmetic brand of L'Oreal S.A., launched a campaign to raise awareness about social media's impact on mental health. As part of the company's 'Brave Together' initiative, the campaign acknowledges both social media's negative and positive impacts and the overall impact these platforms have on the user's well-being. Such campaigns aim to increase public awareness and aid those needing help and medical intervention, thus supporting the market's expansion.

Increasing Research Activities Support Market Expansion

The increasing emphasis on research and development activities to bolster the availability of novel therapeutic solutions and assess the long-term safety and efficacy of different treatment options is positively influencing the expansion of the anxiety disorders and depression treatment market. For instance, Supernus Pharmaceuticals, Inc. is conducting a phase 3 interventional study to evaluate the long-term efficacy and safety of SPN-812 in pediatric attention deficit hyperactivity disorder (ADHD) patients. The study is expected to be completed in September 2026.

Additionally, government agencies, academic institutions, and pharmaceutical companies are also increasingly investing in research and development activities to explore novel therapeutic solutions to improve patient outcomes and address the unmet requirements of the patient population. Research activities are also focusing on the development of next-generation drugs and extensively studying prospective new therapeutic solutions for their efficacy in the management of depression and anxiety. Furthermore, researchers are also aiming to potentially identify biochemical and genetic markers that are associated with depression and anxiety to support the development of targeted therapies that are tailored towards the individual requirements of the patients, improving the efficacy of the treatments.

Retail Pharmacies Account for Significant Market Share

Due to the accessible and reliant nature of retail pharmacies, patients prefer to buy their medications through them. The availability of both branded and generic drugs, along with a wide range of pharmaceutical products at the same place, in combination with the presence of staff to educate the patients about the potential side effects associated with different drugs, is further increasing the popularity of the distribution channel.

Meanwhile, online pharmacies are expected to grow rapidly over the forecast period. This growth can be attributed to the increasing number of apps and e-commerce platforms that provide various medications, including antidepressants, anxiolytics, anticonvulsants, noradrenergic agents, and atypical antipsychotics, among others. The availability of detailed product descriptions, including potential side effects, lucrative deals, and swift shipping and delivery, is also increasing the reliance on online pharmacies. Additionally, full-service online pharmacies, such as Amazon Pharmacy of Amazon.com, Inc., are expanding their same-day delivery service and opening twenty new pharmacies across the United States. In October 2024, the company announced that it will leverage its advanced automation technology and vast logistics network to eliminate one of the biggest challenges of pharmacies: lack of convenience for accessing medication. The company's efforts to expand its same-day delivery service are expected to enhance patient convenience and support the segment's growth.

North America Holds Major Market Share

The rapid growth of the North America anxiety disorders and depression treatment market can be attributed to the availability of treatment solutions across different distribution channels, the strong presence of key market players, and increasing awareness about mental health disorders in the region. The rising cases of depression and anxiety in the region are also bolstering the market's demand. According to the estimates of Mental Health America, approximately 21 million adults in the United States are living with major depression. In countries such as the United States and Canada, mental health has garnered significant attention with substantial government investments in mental health programs and the introduction of initiatives like the National Suicide Prevention Lifeline.

The strong reimbursement policies in the region also provide lucrative growth opportunities for the market. Medicare, a U.S. government program, covers a wide range of generic and brand-name prescription drugs, including antidepressant medications for treating mental health issues. Thus, bolstering their accessibility. Additionally, the rising awareness about various mental health conditions in the region and increasing initiatives by various non-governmental and governmental organizations to increase public awareness about the available treatment options are also positively influencing the expansion of the anxiety disorders and depression treatment market.

Future Market Scenario (2025-2032F)

As per the global anxiety disorders and depression treatment market analysis, the market's growth is supported by shifting cultural perspectives towards mental health in various regions across the globe, increasing availability of the medication across different distribution channels, and rising approvals from regulatory bodies for treatments for depression and anxiety disorders.

Various healthcare organizations, educational institutions, and pharmaceutical companies are also working on research activities to assess the safety and effectiveness of various drugs for depression and anxiety disorders in different age groups. For instance, Children's Hospital Los Angeles is conducting a phase 3 interventional study to assess if fluoxetine medication or cognitive behavioral therapy (CBT) is more effective in improving anxiety symptoms. The study is estimated to be completed in February 2025. Such efforts of the different organizations are busting various myths associated with drugs used for treating mental health disorders and showcasing their efficacy. Additionally, healthcare professionals are taking various measures to augment awareness about the different medications available to cater to the requirements of the diverse patient population.

Moreover, the rapid expansion of telehealth services allows patients to receive affordable, personalized, and accessible treatments, positively influencing the market's expansion.

Key Players Landscape and Outlook

Increasing approvals from the regulatory bodies and growing efforts of the market players to introduce novel products are allowing the market's key players to expand their share in the anxiety disorders and depression treatment market. In July 2024, Johnson & Johnson Services, Inc. announced that they had submitted a supplemental New Drug Application (sNDA) to the US FDA to receive approval for SPRAVATO (esketamine) CIII nasal spray for adults suffering from treatment-resistant depression. The sNDA is supported by positive results from the Phase 4 TRD4005 study conducted to evaluate the tolerability, efficacy, and safety of SPRAVATO as a monotherapy.

In December 2022, AbbVie Inc. announced that the US FDA approved VRAYLAR (cariprazine) as a treatment for major depressive disorder in adults. Such approvals provide patients with novel options that meet their critical requirements and showcase the commitment of the market players in driving progress for complex neuropsychiatric conditions.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Anxiety Disorders and Depression Treatment Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Class
      • 4.2.1.1. Antidepressants
      • 4.2.1.2. Anxiolytics
      • 4.2.1.3. Anticonvulsants
      • 4.2.1.4. Noradrenergic Agents
      • 4.2.1.5. Atypical Antipsychotics
    • 4.2.2. By Indication
      • 4.2.2.1. Anxiety
        • 4.2.2.1.1. Generalized Anxiety
        • 4.2.2.1.2. Panic Disorder
        • 4.2.2.1.3. Obsessive-Compulsive Disorder
        • 4.2.2.1.4. Others
      • 4.2.2.2. Depression
        • 4.2.2.2.1. Major Depressive Disorder
        • 4.2.2.2.2. Bipolar Disorder
        • 4.2.2.2.3. Persistent Depressive Disorder
        • 4.2.2.2.4. Others
    • 4.2.3. By Age Group
      • 4.2.3.1. Adults
      • 4.2.3.2. Adolescents
      • 4.2.3.3. Children
    • 4.2.4. By Condition Severity
      • 4.2.4.1. Mild
      • 4.2.4.2. Moderate
      • 4.2.4.3. Severe
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacies
      • 4.2.5.2. Retail Pharmacies
      • 4.2.5.3. Online Pharmacies
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Drug Class
    • 4.3.2. By Indication
    • 4.3.3. By Age Group
    • 4.3.4. By Condition Severity
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. North America Anxiety Disorders and Depression Treatment Market Outlook, 2018-2032F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. Antidepressants
      • 5.2.1.2. Anxiolytics
      • 5.2.1.3. Anticonvulsants
      • 5.2.1.4. Noradrenergic Agents
      • 5.2.1.5. Atypical Antipsychotics
    • 5.2.2. By Indication
      • 5.2.2.1. Anxiety
        • 5.2.2.1.1. Generalized Anxiety
        • 5.2.2.1.2. Panic Disorder
        • 5.2.2.1.3. Obsessive-Compulsive Disorder
        • 5.2.2.1.4. Others
      • 5.2.2.2. Depression
        • 5.2.2.2.1. Major Depressive Disorder
        • 5.2.2.2.2. Bipolar Disorder
        • 5.2.2.2.3. Persistent Depressive Disorder
        • 5.2.2.2.4. Others
    • 5.2.3. By Age Group
      • 5.2.3.1. Adults
      • 5.2.3.2. Adolescents
      • 5.2.3.3. Children
    • 5.2.4. By Condition Severity
      • 5.2.4.1. Mild
      • 5.2.4.2. Moderate
      • 5.2.4.3. Severe
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Hospital Pharmacies
      • 5.2.5.2. Retail Pharmacies
      • 5.2.5.3. Online Pharmacies
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Anxiety Disorders and Depression Treatment Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Drug Class
          • 5.3.1.2.1.1. Antidepressants
          • 5.3.1.2.1.2. Anxiolytics
          • 5.3.1.2.1.3. Anticonvulsants
          • 5.3.1.2.1.4. Noradrenergic Agents
          • 5.3.1.2.1.5. Atypical Antipsychotics
        • 5.3.1.2.2. By Indication
          • 5.3.1.2.2.1. Anxiety
          • 5.3.1.2.2.1.1. Generalized Anxiety
          • 5.3.1.2.2.1.2. Panic Disorder
          • 5.3.1.2.2.1.3. Obsessive-Compulsive Disorder
          • 5.3.1.2.2.1.4. Others
          • 5.3.1.2.2.2. Depression
          • 5.3.1.2.2.2.1. Major Depressive Disorder
          • 5.3.1.2.2.2.2. Bipolar Disorder
          • 5.3.1.2.2.2.3. Persistent Depressive Disorder
          • 5.3.1.2.2.2.4. Others
        • 5.3.1.2.3. By Age Group
          • 5.3.1.2.3.1. Adults
          • 5.3.1.2.3.2. Adolescents
          • 5.3.1.2.3.3. Children
        • 5.3.1.2.4. By Condition Severity
          • 5.3.1.2.4.1. Mild
          • 5.3.1.2.4.2. Moderate
          • 5.3.1.2.4.3. Severe
        • 5.3.1.2.5. By Distribution Channel
          • 5.3.1.2.5.1. Hospital Pharmacies
          • 5.3.1.2.5.2. Retail Pharmacies
          • 5.3.1.2.5.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Anxiety Disorders and Depression Treatment Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Anxiety Disorders and Depression Treatment Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Anxiety Disorders and Depression Treatment Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Anxiety Disorders and Depression Treatment Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. AbbVie Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 20.3.2. Pfizer Inc.
    • 20.3.3. GlaxoSmithKline plc
    • 20.3.4. Merck & Co., Inc.
    • 20.3.5. Bristol-Myers Squibb Company
    • 20.3.6. AstraZeneca plc
    • 20.3.7. Eli Lilly and Company
    • 20.3.8. Johnson & Johnson Services, Inc.
    • 20.3.9. H. Lundbeck A/S
    • 20.3.10. Sanofi S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 3. Global Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 4. Global Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 5. Global Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 6. Global Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 7. Global Anxiety Disorders and Depression Treatment Market Share (%), By Region, 2018-2032F
  • Figure 8. North America Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 9. North America Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 10. North America Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 11. North America Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 12. North America Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 13. North America Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 14. North America Anxiety Disorders and Depression Treatment Market Share (%), By Country, 2018-2032F
  • Figure 15. United States Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. United States Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 17. United States Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 18. United States Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 19. United States Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 20. United States Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 21. Canada Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 22. Canada Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 23. Canada Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 24. Canada Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 25. Canada Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 26. Canada Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Mexico Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 28. Mexico Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 29. Mexico Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 30. Mexico Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 31. Mexico Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 32. Mexico Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 34. Europe Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 35. Europe Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 36. Europe Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 37. Europe Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 38. Europe Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. Europe Anxiety Disorders and Depression Treatment Market Share (%), By Country, 2018-2032F
  • Figure 40. Germany Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. Germany Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 42. Germany Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 43. Germany Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 44. Germany Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 45. Germany Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 46. France Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 47. France Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 48. France Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 49. France Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 50. France Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 51. France Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Italy Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Italy Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 54. Italy Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 55. Italy Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 56. Italy Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 57. Italy Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 58. United Kingdom Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 59. United Kingdom Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 60. United Kingdom Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 61. United Kingdom Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 62. United Kingdom Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 63. United Kingdom Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Russia Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Russia Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 66. Russia Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 67. Russia Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 68. Russia Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 69. Russia Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 70. Netherlands Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 71. Netherlands Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 72. Netherlands Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 73. Netherlands Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 74. Netherlands Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 75. Netherlands Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 76. Spain Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 77. Spain Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 78. Spain Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 79. Spain Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 80. Spain Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 81. Spain Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 82. Turkey Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. Turkey Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 84. Turkey Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 85. Turkey Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 86. Turkey Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 87. Turkey Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 88. Poland Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 89. Poland Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 90. Poland Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 91. Poland Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 92. Poland Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 93. Poland Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. South America Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. South America Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 96. South America Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 97. South America Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 98. South America Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 99. South America Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. South America Anxiety Disorders and Depression Treatment Market Share (%), By Country, 2018-2032F
  • Figure 101. Brazil Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. Brazil Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 103. Brazil Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 104. Brazil Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 105. Brazil Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 106. Brazil Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 107. Argentina Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 108. Argentina Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 109. Argentina Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 110. Argentina Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 111. Argentina Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 112. Argentina Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 113. Asia-Pacific Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 114. Asia-Pacific Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 115. Asia-Pacific Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 116. Asia-Pacific Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 117. Asia-Pacific Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 118. Asia-Pacific Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 119. Asia-Pacific Anxiety Disorders and Depression Treatment Market Share (%), By Country, 2018-2032F
  • Figure 120. India Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 121. India Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 122. India Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 123. India Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 124. India Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 125. India Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 126. China Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. China Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 128. China Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 129. China Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 130. China Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 131. China Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 132. Japan Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 133. Japan Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 134. Japan Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 135. Japan Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 136. Japan Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 137. Japan Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 138. Australia Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 139. Australia Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 140. Australia Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 141. Australia Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 142. Australia Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 143. Australia Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 144. Vietnam Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 145. Vietnam Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 146. Vietnam Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 147. Vietnam Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 148. Vietnam Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 149. Vietnam Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 150. South Korea Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 151. South Korea Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 152. South Korea Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 153. South Korea Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 154. South Korea Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 155. South Korea Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 156. Indonesia Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 157. Indonesia Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 158. Indonesia Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 159. Indonesia Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 160. Indonesia Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 161. Indonesia Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. Philippines Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 163. Philippines Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 164. Philippines Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 165. Philippines Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 166. Philippines Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 167. Philippines Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 168. Middle East & Africa Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 169. Middle East & Africa Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 170. Middle East & Africa Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 171. Middle East & Africa Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 172. Middle East & Africa Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 173. Middle East & Africa Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 174. Middle East & Africa Anxiety Disorders and Depression Treatment Market Share (%), By Country, 2018-2032F
  • Figure 175. Saudi Arabia Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 176. Saudi Arabia Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 177. Saudi Arabia Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 178. Saudi Arabia Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 179. Saudi Arabia Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 180. Saudi Arabia Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 181. UAE Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 182. UAE Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 183. UAE Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 184. UAE Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 185. UAE Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 186. UAE Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 187. South Africa Anxiety Disorders and Depression Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 188. South Africa Anxiety Disorders and Depression Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 189. South Africa Anxiety Disorders and Depression Treatment Market Share (%), By Indication, 2018-2032F
  • Figure 190. South Africa Anxiety Disorders and Depression Treatment Market Share (%), By Age Group, 2018-2032F
  • Figure 191. South Africa Anxiety Disorders and Depression Treatment Market Share (%), By Condition Severity, 2018-2032F
  • Figure 192. South Africa Anxiety Disorders and Depression Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 193. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 194. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 195. By Age Group Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 196. By Condition Severity Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024